Premium
Neuroprotective effect of the glucagon‐like peptide‐1 receptor agonist, synthetic exendin‐4, in streptozotocin‐induced diabetic rats
Author(s) -
Liu Wei Jing,
Jin Heung Yong,
Lee Kyung Ae,
Xie Shu Hua,
Baek Hong Sun,
Park Tae Sun
Publication year - 2011
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2011.01272.x
Subject(s) - agonist , streptozotocin , neuroprotection , glucagon like peptide 1 , receptor , endocrinology , medicine , glucagon like peptide 1 receptor , pharmacology , chemistry , diabetes mellitus , type 2 diabetes
BACKGROUND AND PURPOSE Glucagon‐like peptide‐1 (GLP‐1) receptors are widely expressed in neural tissues and diminish neuronal degeneration or induce neuronal differentiation. The aim of this study was to investigate the effect of the GLP‐1 pathway on peripheral nerves in streptozotocin‐induced diabetic rats. EXPERIMENTAL APPROACH Diabetic and nondiabetic rats were treated with the GLP‐1 receptor agonist, synthetic exendin‐4 (i.p., 1 nmol·kg −1 ·day −1 ) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured. We also investigated GLP‐1 receptor expression, quantitative changes in PGP9.5‐positive intraepidermal nerve fibres and cleaved caspase 3–stained Schwann cells by immunohistochemistry. KEY RESULTS GLP‐1 receptor expression was detected in the sciatic nerve and skin. After exendin‐4 treatment, the increase seen in current perception threshold values at 2000 and 250 Hz in diabetic rats was reduced. Also, the decrease in myelinated fibre size or axon/fibre area ratio in the sciatic nerve and the loss of intraepidermal nerve fibre in the skin of diabetic rats were ameliorated. These responses were closely associated with the attenuation of Schwann cell apoptosis and improvement in the cAMP level in exendin‐4‐treated diabetic rats, compared with placebo‐treated animals. CONCLUSION AND IMPLICATIONS Synthetic exendin‐4 may prevent peripheral nerve degeneration induced by diabetes in an animal model, supporting the hypothesis that GLP‐1 may be useful in peripheral neuropathy. The neuroprotection is probably attributable to GLP‐1 receptor activation, antiapoptotic effects and restoration of cAMP content.